Literature DB >> 25965437

Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting.

Kelly Warren Burak, Morris Sherman.   

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and its incidence has rapidly increased in North America in recent years. Although there are many published guidelines to assist the clinician, there remain gaps in knowledge and areas of controversy surrounding the diagnosis and management of HCC. In February 2014, the Canadian Association for the Study of the Liver organized a one-day single-topic consensus conference on HCC. Herein, the authors present a summary of the topics covered and the result of voting on consensus statements presented at this meeting.

Entities:  

Mesh:

Year:  2015        PMID: 25965437      PMCID: PMC4444026          DOI: 10.1155/2015/824263

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  42 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

3.  Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.

Authors:  Ramón Vilana; Alejandro Forner; Luis Bianchi; Angeles García-Criado; Jordi Rimola; Carlos Rodríguez de Lope; María Reig; Carmen Ayuso; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

Review 6.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

Review 7.  Burden of disease and cost of chronic hepatitis C infection in Canada.

Authors:  Robert P Myers; Mel Krajden; Marc Bilodeau; Kelly Kaita; Paul Marotta; Kevork Peltekian; Alnoor Ramji; Chris Estes; Homie Razavi; Morris Sherman
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

8.  SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more
  15 in total

1.  Comparison of the efficacy of pre-surgery and post-surgery radiotherapy in the treatment of hepatocellular carcinoma: a population-based study.

Authors:  Lei Chen; Xiaopeng Guo; Shi Chen; Yanqiao Ren; Tao Sun; Fan Yang; Chuansheng Zheng
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Current locoregional therapies and treatment strategies in hepatocellular carcinoma.

Authors:  L Cardarelli-Leite; A Hadjivassiliou; D Klass; J Chung; S G F Ho; H J Lim; P T W Kim; A Mujoomdar; D M Liu
Journal:  Curr Oncol       Date:  2020-11-01       Impact factor: 3.677

3.  Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B.

Authors:  Tamara Leah Remington; Mariam Osman; Kimberley Simmonds; Carmen L Charlton; Karen Doucette
Journal:  Can Liver J       Date:  2020-08-20

4.  Hepatocellular carcinoma screening practices among patients with chronic hepatitis B by Canadian gastroenterologists and hepatologists: An online survey.

Authors:  Alan Hoi Lun Yau; Cherry Galorport; Carla S Coffin; Hin Hin Ko
Journal:  Can Liver J       Date:  2019-12-10

Review 5.  Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma.

Authors:  Chen-Yi Liao; Ching-Chang Lee; Chi-chang Tsai; Chao-Wen Hsueh; Chih-Chiang Wang; I-Hung Chen; Ming-Kai Tsai; Mei-Yu Liu; An-Tie Hsieh; Kuan-Jen Su; Hau-Ming Wu; Shih-Chung Huang; Yi-Chen Wang; Chien-Yao Wang; Shu-Fang Huang; Yen-Cheng Yeh; Ren-Jy Ben; Shang-Tao Chien; Chin-Wen Hsu; Wu-Hsien Kuo
Journal:  Biomed Res Int       Date:  2015-12-16       Impact factor: 3.411

6.  Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.

Authors:  Hla-Hla Thein; Wanrudee Isaranuwatchai; Yao Qiao; Kenny Wong; Gonzalo Sapisochin; Kelvin K W Chan; Eric M Yoshida; Craig C Earle
Journal:  Cancer Med       Date:  2017-08-08       Impact factor: 4.452

7.  Effects of LncRNA-HOST2 on cell proliferation, migration, invasion and apoptosis of human hepatocellular carcinoma cell line SMMC-7721.

Authors:  Run-Tian Liu; Jing-Lin Cao; Chang-Qing Yan; Yang Wang; Cong-Jing An; Hai-Tao Lv
Journal:  Biosci Rep       Date:  2017-04-20       Impact factor: 3.840

8.  Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.

Authors:  Hla-Hla Thein; Yao Qiao; Ahmad Zaheen; Nathaniel Jembere; Gonzalo Sapisochin; Kelvin K W Chan; Eric M Yoshida; Craig C Earle
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

9.  HCC screening: assessment of an abbreviated non-contrast MRI protocol.

Authors:  Michael Vinchill Chan; Stephen J McDonald; Yang-Yi Ong; Katerina Mastrocostas; Edwin Ho; Ya Ruth Huo; Cositha Santhakumar; Alice Unah Lee; Jessica Yang
Journal:  Eur Radiol Exp       Date:  2019-12-18

Review 10.  Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints.

Authors:  Sunmin Park; Won Sup Yoon; Chai Hong Rim
Journal:  World J Gastroenterol       Date:  2020-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.